Back to Search
Start Over
A case of tocilizumab-refractory idiopathic multicentric Castleman's disease successfully treated with sirolimus
- Source :
- Clinical Immunology. 233:108887
- Publication Year :
- 2021
- Publisher :
- Elsevier BV, 2021.
-
Abstract
- Keymessage mTOR signaling may be a new therapeutic target for IL-6 inhibitor refractory iMCD-NOS.
Details
- ISSN :
- 15216616
- Volume :
- 233
- Database :
- OpenAIRE
- Journal :
- Clinical Immunology
- Accession number :
- edsair.doi...........4a58351c8d16114e1672432bb442a99d
- Full Text :
- https://doi.org/10.1016/j.clim.2021.108887